ClinVar Miner

Submissions for variant NM_000518.4(HBB):c.19G>A (p.Glu7Lys) (rs33930165)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000224028 SCV000280895 pathogenic not provided 2014-09-15 criteria provided, single submitter clinical testing
GeneDx RCV000224028 SCV000321759 pathogenic not provided 2018-06-14 criteria provided, single submitter clinical testing The E7K (also referred to as E6K, due to alternate nomenclature) pathogenic variant results in HbC, a structural variant of normal hemoglobin. It is one of the most prevalent abnormal hemoglobin variants globally alongside hemoglobin S (Cook et al., 2013; Piel et al., 2013). E7K has been reported in the homozygous state, or compound heterozygous state, along with a second hemoglobin variant, in numerous individuals with hemoglobin C disease (Cook et al., 2013). When inherited along with a second HBB pathogenic variant, compound heterozygosity could also result in other clinically significant hemoglobinopathis such as sickle-hemoglobin C disease and hemoglobin C-beta thalassemia (Piel et al., 2013). HbC allele frequencies above 15% have been described in West African populations, and the estimated carrier frequency for HbC in the African American population is 1/31 (Piel et al., 2013; Tabor et al., 2014). The E7K variant is a non-conservative amino acid substitution, which occurs at a position that is not conserved across species. Functional studies have shown that the E7K variant reduces the overall hydrophobicity as compared to wild type hemoglobin (Adachi et al., 1987). In silico analysis predicts that E7K shows a difference in charge that will disturb the ionic interaction of the original wild type residue, which could possibly disrupt contacts with other molecules as well as disturb the interaction with the other parts of the protein (Alanzai et al., 2011). We interpret E7K as a pathogenic variant.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000999923 SCV000603913 pathogenic not specified 2018-07-05 criteria provided, single submitter clinical testing The Hb C variant (HBB: c.19G>A; p.Glu7Lys, also known as Glu6Lys when numbered from the mature protein) is a common pathogenic beta globin variant. Heterozygosity is consistent with Hb C trait. Homozygosity is consistent with a clinical presentation of mild to moderate hemolytic anemia with mild microcytosis and frequent target cells. Hb C in combination with a beta thalassemia variant on the opposite chromosome is often associated with mild microcytic anemia (Cook 2013, HbVar database). REFERENCES Link to HbVar database for Hb C: Cook C et al. The clinical and laboratory spectrum of Hb C (beta6(A3)Glu>Lys, GAG>AAG) disease. Hemoglobin. 2013; 37(1):16-25.
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000224028 SCV000700666 pathogenic not provided 2017-06-07 criteria provided, single submitter clinical testing
Invitae RCV000224028 SCV000930769 pathogenic not provided 2019-12-31 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with lysine at codon 7 of the HBB protein (p.Glu7Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is present in population databases (rs33930165, ExAC 1.4%). This is a common, well-known variant that has been observed in individuals affected with beta-hemoglobinopathies (PMID: 20301551, 26372199, 23297836, 27117572). It is also known as p.Glu6Lys and HbC in the literature. ClinVar contains an entry for this variant (Variation ID: 15126). Experimental studies have shown that this variant affects the kinetic properties of the hemoglobin protein (PMID: 2888754). For these reasons, this variant has been classified as Pathogenic.
Mendelics RCV000576347 SCV001138223 pathogenic beta Thalassemia 2019-05-28 criteria provided, single submitter clinical testing
Baylor Genetics RCV000202507 SCV001163297 pathogenic Hb SS disease criteria provided, single submitter clinical testing
Myriad Women's Health, Inc. RCV000576347 SCV001194071 pathogenic beta Thalassemia 2019-11-15 criteria provided, single submitter clinical testing NM_000518.4(HBB):c.19G>A(E7K, aka Hb C) is classified as pathogenic in the context of Hb beta chain-related hemoglobinopathy and is associated with the hemoglobin C form of disease. Sources cited for classification include the following: PMID 23297836, 23297836, 19061217 and 2888754. Classification of NM_000518.4(HBB):c.19G>A(E7K, aka Hb C) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.
OMIM RCV000016284 SCV000036552 pathogenic HEMOGLOBIN C 2011-12-02 no assertion criteria provided literature only
OMIM RCV000016285 SCV000036553 protective Malaria, resistance to 2011-12-02 no assertion criteria provided literature only
GeneReviews RCV000202507 SCV000190689 pathogenic Hb SS disease 2014-10-23 no assertion criteria provided literature only
Reproductive Health Research and Development,BGI Genomics RCV000576347 SCV001142415 pathogenic beta Thalassemia 2020-01-06 no assertion criteria provided curation NM_000518.4:c.19G>A is also known as p.Glu6Lys or HbC in the literature. NM_000518.4:c.19G>A in the HBB gene has an allele frequency of 0.013 in African subpopulation in the gnomAD database. Boucher et al. reported Mild Microcytic Anemia in an Infant with a compound heterozygosity for Hb C (HBB: c.19G > A) and Hb Osu Christiansborg (HBB:c.157G > A) (PMID: 27117572). In addition, this variant was reported as the most common emoglobin (Hb) abnormality identified in the United States (PMID: 23297836). Experimental studies have shown that this variant affects the kinetic properties of the hemoglobin protein (PMID: 2888754). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PS4; PS3; PM3; PP4.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.